The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | Considering the role of autologous transplantation in DLBCL at first relapse
In this video, Chris Fox, MBChB(Hons), MRCP, FRCPath, Nottingham University Hospitals NHS Trust – City Campus, Nottingham, UK, briefly comments on the role of autologous stem cell transplantation (autoSCT) in patients with diffuse large B-cell lymphoma (DLBCL) at first relapse who are chemosensitive. Prof. Fox highlights that, although no direct comparison has been performed, it appears that autoSCT may offer comparable outcomes to CAR T-cell therapy in this patient population. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, at this EBMT meeting, I’m really pleased to be involved in the Lymphoma Working Party session where I’ve been given the task of debating the role of autologous transplant versus CAR T-cell therapy for patients with relapsed diffuse large B-cell lymphoma at first relapse who are chemosensitive. So this is a challenging area where there are different opinions...
So, at this EBMT meeting, I’m really pleased to be involved in the Lymphoma Working Party session where I’ve been given the task of debating the role of autologous transplant versus CAR T-cell therapy for patients with relapsed diffuse large B-cell lymphoma at first relapse who are chemosensitive. So this is a challenging area where there are different opinions. The case for autologous transplant points to a number of mainly retrospective datasets, led dominantly by the CIBMTR, showing that patients who remain chemosensitive at relapse, defined as a partial response or better by either CT or PET, can experience very good survival outcomes in that setting. And although there’s no direct comparison against CAR-T for that particular chemosensitive group, the outcomes look comparable.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Consultancy: AbbVie, Arvinas, BMS, GenMab, Gilead/Kite, Incyte, Morphosys, Ono, Roche, SERB, SOBI; Speaker honoraria: AbbVie, Gilead/Kite, Incyte, Roche, SERB; Research funding to Institution from Beigene, Incyte, Abbvie/Genmab.
